Olezarsen: FDA approval and clinical impact in familial chylomicronemia syndrome (FCS).

Ann Med Surg (Lond) · 2025 · PMC12577896 · PMID 41180755

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The primary endpoint was the percent change in fasting TG levels from baseline [ 21 ] The 80 mg group achieved a 43.5 percentage point reduction in TGs compared to placebo ( P < 0.001), whereas the 50 mg group did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.